- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEWBURY PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09:00 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury | 185 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Tofacitinib Newbury 5 mg and 10 mg film-coated tablets in Sweden as the first country in a Scandinavian... ► Artikel lesen | |
| Fr | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury | 1.352 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Dalbavancin Newbury 500 mg powder for concentrate for solution for infusion in Sweden. No further country... ► Artikel lesen | |
| Mi | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - May 2026 | 99 | GlobeNewswire (Europe) | Quarter 3, March 2026 - May 2026Net revenue was 8 933 (6 686) tkr.EBITDA was -3 964 (-5 691) tkr.Operating cash flow was -10 286 (-5 787) tkr.Interim period, September 2025 - May 2026Net revenue was... ► Artikel lesen | |
| 15.04. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - February 2026 | 136 | GlobeNewswire (Europe) | Quarter 2, December 2025 - February 2026Net revenue was 8 454 (12 434) tkr.EBITDA was -4 144 (-973) tkr.Operating cash flow was 2 260 (-6 371) tkr.Interim period, September 2025 - February 2026Net revenue... ► Artikel lesen | |
| 26.03. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM | 178 | GlobeNewswire (Europe) | Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and... ► Artikel lesen | |
| 18.03. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets | 213 | GlobeNewswire (Europe) | Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the... ► Artikel lesen | |
| 29.01. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark | 175 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce that it has been awarded a 12-month tender for Pazopanib Newbury with the Danish procurement body Amgros, commencing on June 1, 2026.
Pazopanib Newbury... ► Artikel lesen | |
| 21.01. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - November 2025 | 192 | GlobeNewswire (Europe) | Quarter 1, September 2025 - November 2025Net revenue was 11 720 (6 538) tkr.EBITDA was -5 524 (-3 759) tkr.Operating cash flow was -6 549 (4 792) tkr.Cash position in the end of period was 7 919 (19... ► Artikel lesen | |
| 11.11.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO | 261 | GlobeNewswire (Europe) | The company today announced that Karl Karlsson, currently Executive Chairman of the Board, has been appointed CEO of Newbury Pharmaceuticals AB.
Lars Minor is simultaneously stepping down from his role... ► Artikel lesen | |
| 29.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals year-end report September 2024 - August 2025 | 234 | GlobeNewswire (Europe) | Quarter 4, June 2025 - August 2025Net revenue was 5 915 (21 123) tkr.EBITDA was -5 876 (2 402) tkr.Operating cash flow was -5 004 (130) tkr.Year-end period, September 2024 - August 2025Net revenue was... ► Artikel lesen | |
| 24.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury | 208 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in Sweden.
Mirtazapin Newbury is a noradrenergic and specific... ► Artikel lesen | |
| 23.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury | 223 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Ivermectin Newbury 10 mg/g cream in Denmark as the first country in a Scandinavian registration procedure.... ► Artikel lesen | |
| 11.08.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury | 242 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release tablets in Finland as the first country in a Nordic registration... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,20 | -0,99 % | Märkte am Morgen: Bayer, Deutsche Bank, SAP, Delivery Hero, Easyjet, ASML | Der DAX hat in der vergangenen Woche abgeliefert. Ein Plus von 4,5 Prozent bedeutet die beste Handelswoche seit April 2025. Vor allem an den letzten Tagen blies der DAX zur Rekordjagd, stellte eine... ► Artikel lesen | |
| MERCK KGAA | 138,65 | -0,68 % | Aktien Frankfurt Ausblick: Dax kaum bewegt nach Rekord | FRANKFURT (dpa-AFX) - Nach seinem Rekordlauf in der vergangenen Woche dürfte der Dax am Montag seine Gewinne halten. Stützend wirken teils freundliche Aktienmärkte in Asien. Dort sorge die Aussicht... ► Artikel lesen | |
| PMGC | 1,110 | -0,89 % | PMGC Holdings Inc.: NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression | Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously... ► Artikel lesen | |
| NOVO NORDISK | 43,205 | -0,39 % | Novo Nordisk: Kursziel rauf | Stück für Stück arbeitet sich die Aktie von Novo Nordisk aus dem Tal der Tränen. Zum Start in die neue Handelswoche verbucht das Papier des dänischen Biopharma-Konzerns an der Heimatbörse in Kopenhagen... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,540 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,84 | 0,00 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| KARDIGAN | 24,550 | -0,34 % | JPMorgan initiates Kardigan stock with overweight on pipeline | ||
| ETON PHARMACEUTICALS | 36,720 | +0,30 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 38,6 USD | ||
| LB PHARMACEUTICALS | 32,950 | 0,00 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ||
| PFIZER | 21,240 | +0,21 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Pfizer von 30 auf 28 US-Dollar gesenkt und die Einstufung auf "Neutral" belassen. Seine Schätzungen für die Quartalszahlen am... ► Artikel lesen | |
| ELI LILLY | 1.041,00 | 0,00 % | Megatrend Folger: Eli Lilly sprengt die Billionen-Marke | Eli Lilly marschiert weiter an der Spitze des globalen Gesundheitssektors. Die Aktie des US-Pharmagiganten kletterte am Dienstag auf ein neues Allzeithoch und lässt damit die Marke von einer Billion... ► Artikel lesen | |
| CHINA PHARMA HOLDINGS | 0,635 | 0,00 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| VYNE THERAPEUTICS | 0,642 | +0,66 % | VYNE Therapeutics Inc.: VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience | NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash... ► Artikel lesen | |
| ASTRAZENECA | 149,05 | -0,86 % | BERNSTEIN RESEARCH stuft ASTRAZENECA auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18600 auf 18900 Pence angehoben und die Einstufung auf "Outperform" belassen. Vielversprechende... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 2,040 | 0,00 % | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen |
NEWBURY PHARMACEUTICALS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,028 (+18,67 %) liegt der Kurs bei 0,178 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWBURY PHARMACEUTICALS AB finden Sie auf Wallstreet Online.